| DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. | DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M., Free PMC Article | 11/12/2022 |
| ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China. | ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C, Dong J, Liu L, Liu J, Sun X, Teng F, Wang X, Ying J, Li J, Xing P, Yang L., Free PMC Article | 03/26/2022 |
| TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. | TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
Miyagawa-Hayashino A, Okada S, Takeda-Miyata N, Takashima Y, Yamada T, Takemura Y, Uchino J, Inoue M, Takayama K, Konishi E., Free PMC Article | 12/25/2021 |
| Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis. | Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis.
Liu Q, Song X, Liu Z, Yu Z., Free PMC Article | 12/18/2021 |
| A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer. | A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S, Voynov V, Drobits-Handl B, Giragossian C, Trapani F, Nixon AE, Scheer JM, Adam PJ. | 11/27/2021 |
| Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. | Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. | 11/27/2021 |
| DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC. | DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Ogawa H, Sakai Y, Nishio W, Fujibayashi Y, Nishikubo M, Nishioka Y, Tane S, Kitamura Y, Sudo T, Sakuma T, Yoshimura M., Free PMC Article | 11/22/2021 |
| Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview. | Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.
Matsuo K, Taniguchi K, Hamamoto H, Inomata Y, Komura K, Tanaka T, Lee SW, Uchiyama K., Free PMC Article | 08/21/2021 |
| DLL3 is expressed at high frequency (74%) in stage IV pulmonary large cell neuroendocrine carcinoma and is a potential therapy target. | DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, Smit EF, Damhuis RA, van den Broek EC, PALGA-group, Ruland A, Speel EJM, Dingemans AMC. | 09/5/2020 |
| DLL3 expression is reliably quantifiable by pathologists and is highly expressed in the majority of SCLC and a subset of carcinoid tumors, making it an attractive target for anti-DLL3 treatment. | Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H, Boland JM, Maleszewski JJ, Aubry MC, Yi ES, Jenkins SM, Koepplin JW, Terra SBSP, Mansfield AS, Roden AC. | 07/18/2020 |
| LIN28B and miR-518d-5p could regulate DLL3-mediated cell proliferation and migration. | DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J, Cao D, Sha J, Zhu X, Han S. | 06/20/2020 |
| Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed in Small cell lung cancer (SCLC) and other neuroendocrine tumors but minimally expressed in normal tissues. It is therefore being explored as a potential therapeutic target in SCLC. [review] | DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K., Free PMC Article | 06/20/2020 |
| DLL3 is selectively and homogeneously expressed in IDH-mutant gliomas and can be targeted with Rova-T in patient-derived IDH-mutant glioma tumorspheres. | Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS., Free PMC Article | 04/25/2020 |
| DLL3 is preferentially expressed in castration-resistant neuroendocrine prostate cancer and provide rationale for targeting DLL3 in patients with DLL3-positive metastatic prostate cancer. | Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H., Free PMC Article | 04/18/2020 |
| Overexpression of DLL3 mRNA and protein is common in small-cell bladder cancer (SCBC) and correlates with shorter overall survival . A DLL3-targeted antibody-drug conjugate demonstrated in vivo efficacy superior to chemotherapy in a PDX model of SCBC. | Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.
Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P., Free PMC Article | 02/29/2020 |
| Results showed that DLL3 localized in normal neuroendocrine cells. Considerable upregulation of DLL3 was found in gastrointestinal neuroendocrine carcinoma cell lines. Its silencing caused significant growth inhibition and induction of intrinsic apoptosis. This study suggests that DLL3, expressed in neuroendocrine cells of the gastrointestinal tract, has a pivotal role in gastrointestinal neuroendocrine carcinoma. | Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy.
Matsuo K, Taniguchi K, Hamamoto H, Ito Y, Futaki S, Inomata Y, Shima T, Asakuma M, Lee SW, Tanaka K, Okuda J, Kondo Y, Uchiyama K., Free PMC Article | 10/12/2019 |
| DLL3 expression is silenced during hepatocarcinogenesis in association with HBV infection via an epigenetic mechanism | Delta-like 3 is silenced by HBx via histone acetylation in HBV-associated HCCs.
Hamamoto H, Maemura K, Matsuo K, Taniguchi K, Tanaka Y, Futaki S, Takeshita A, Asai A, Hayashi M, Hirose Y, Kondo Y, Uchiyama K., Free PMC Article | 09/28/2019 |
| Results showed that DLL3 downregulation attenuated small cell lung cancer (SCLC)-cell proliferation, migration and invasion in a process involving the attenuation of Snail activation. In addition, DLL3 overexpression promoted subcutaneous tumor growth in the mouse models. | DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J., Free PMC Article | 05/18/2019 |
| The DLL3 expression could be a potential and novel tumor marker for early diagnosis and an independent predictor of poor survival for patients with endometrial cancer | Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer: A retrospective study.
Wang J, Zhang K, Liu Z, Wang T, Shi F, Zhang Y, Su J, Jia Y., Free PMC Article | 03/2/2019 |
| these results reveal that DLL3 is expressed in tumor specimens from most patients with small cell lung cancer | Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I. | 12/22/2018 |
| Results indicated that DLL3 expression was silenced in hepatocellular carcinoma (HCC) cells by DNA methylation and was more readily affected by histone acetylation than histone methylation (H3K9me2 or H3K27me3). | Expression of delta-like 3 is downregulated by aberrant DNA methylation and histone modification in hepatocellular carcinoma.
Mizuno Y, Maemura K, Tanaka Y, Hirata A, Futaki S, Hamamoto H, Taniguchi K, Hayashi M, Uchiyama K, Shibata MA, Otsuki Y, Kondo Y. | 09/1/2018 |
| our results indicated epidermal growth factor-like domain multiple 7 protein participates in growth hormone-secreting pituitary adenoma proliferation and invasion regulation via Notch2/DLL3 signaling pathway. These findings raised the possibility that epidermal growth factor-like domain multiple 7 protein might serve as a useful biomarker to assess growth hormone-secreting pituitary adenoma invasion and prognosis | EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway.
Wang J, Liu Q, Gao H, Wan D, Li C, Li Z, Zhang Y. | 07/29/2017 |
| The Dll3 was rarely detectable in the para-carcinoma tissues, but positive in 82.1% of non-small cell cancer tissues. | The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice.
Deng SM, Yan XC, Liang L, Wang L, Liu Y, Duan JL, Yang ZY, Chang TF, Ruan B, Zheng QJ, Han H. | 06/24/2017 |
| Both global haplotype and individual haplotype analyses showed that the haplotypes of SNP1/SNP2/SNP3/SNP4/SNP5 did not correlate with the disease (P >0.05). Together, these data suggest that genetic variants of the DLL3 gene are not associated with CS in the Chinese Han population. | Five known tagging DLL3 SNPs are not associated with congenital scoliosis: A case-control association study in a Chinese Han population.
Yang Y, Wang BQ, Wu ZH, Zhang HY, Qiu GX, Shen JX, Zhang JG, Zhao Y, Wang YP, Fei Q., Free PMC Article | 02/18/2017 |
| DLL3 was silenced by methylation in human human hepatocellular carcinoma and it negatively regulates the growth of human hepatocellular carcinoma cells. | Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma.
Maemura K, Yoshikawa H, Yokoyama K, Ueno T, Kurose H, Uchiyama K, Otsuki Y., Free PMC Article | 07/20/2013 |